(Q46484331)

22 December 2017

title

B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid (English)

1 reference

22 December 2017

primary biliary cholangitis

main subject

0 references

1 reference

Robert P Myers

1

1 reference

22 December 2017

Mark G Swain

2

1 reference

22 December 2017

Samuel S Lee

3

1 reference

22 December 2017

Abdel Aziz M Shaheen

4

1 reference

22 December 2017

Kelly W Burak

5

1 reference

22 December 2017

language of work or name

English

0 references

publication date

7 May 2013

1 reference

22 December 2017

The American Journal of Gastroenterology

published in

1 reference

22 December 2017

volume

108

1 reference

22 December 2017

issue

6

1 reference

22 December 2017

page(s)

933-941

1 reference

22 December 2017

Primary biliary cirrhosis

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Pathogenesis of cholestatic liver disease and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Epitope mapping and reactivity of autoantibodies to the E2 component of 2-oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2-oxoglutarate dehydrogenase complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

B lymphocyte depletion therapy with rituximab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Rituximab: a promising therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

B cell depletion therapy exacerbates murine primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

B-lymphocyte contributions to human autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Rituximab treatment of idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Treatment of IgM antibody associated polyneuropathies using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Pathophysiology of itch and new treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2013.51

21 January 2018

Identifiers

DOI

10.1038/AJG.2013.51

1 reference

22 December 2017

1 reference

22 December 2017